Last Price$89.69NASDAQ Previous Close - Last Trade as of 4:00PM ET 10/23/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$87.80 (1)
Ask (Size)$89.69 (77)
Day Low / HighN/A - N/A
Volume652.0 K

Eli Lilly, Incyte Report Positive Data from Trial of Baricitinib, Remdesivir Combination to Treat COVID-19

8:59AM ET 9/14/2020 MT Newswires
Eli Lilly and Company (LLY) and pharmaceutical company Incyte (INCY) reported positive initial data from their COVID-19 treatment trial sponsored by the National Institute of Allergy and Infectious Diseases.

The trial included more than 1,000 patients to assess the efficacy and safety of a 4-mg dose of baricitinib plus remdesivir versus remdesivir in hospitalized patients with COVID-19. Baricitinib in combination with remdesivir met the primary endpoint of reduction of time to recovery in comparison with remdesivir.

The companies said study investigators noted an approximately one-day reduction in median recovery time for the overall patient population treated with COVID-19 in combination with remdesivir versus those treated with remdesivir. They also noted that the finding is statistically significant.

Price: 148.09, Change: +1.87, Percent Change: +1.28